ProQR dosed first participant in Phase 1 AX-0811 study
ProQR Therapeutics N.V. announced the first participant was dosed in its Phase 1 study of AX-0811, alongside a Virtual Investor and Analyst Educational Event scheduled for September 30, 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
ProQR announces first participant dosed in Phase 1 of AX-0811
ProQR says it has dosed the first participant in its Phase 1 study of AX-0811.